Partnering opportunities

A DC subset with superior antigen-presenting capability, engineered with a proprietary CAR design for immunotherapy.

Synthetic lethal targeting of MARCH5 to enhance Venetoclax efficacy.

Delivery of a cancer-selective mRNA therapeutic that targets APOBEC enzymes.

A new therapy for global prevention of hemolytic disease of the newborn

Method to induce stem-like memory T cells for long-lived response in vaccine design

Degradation of c-Rel for treating chronic autoimmune inflammatory disease.

Targeting negative regulators of inflammatory cytokine signalling in autoimmune disease.

Developing a first-in-class, anti-NINJ1 therapy for cell death associated diseases.

A media cocktail and culture system for in vitro human haematopoiesis.

Oral therapeutic targeting diverse coronavirus PLpros; potential to minimise progression to severe disease and post-acute sequelae of COVID-19 (PASC / Long COVID).

Oral therapeutic targeting coronavirus Mpro; potential to minimise progression to severe disease and post-acute sequelae of COVID-19 (PASC / Long COVID).

A high throughput diagnostic for relapsing liver malaria.

A high-throughput laboratory-based diagnostic for detecting hidden or cryptic liver stage Plasmodium vivax infections.

Using an epigenetic approach to turn on genes, the absence of which causes Prader Willi Syndrome, a devistating neurodevelopment disorder

An effective and affordable plunge freezing device for cryogenic electron microscopy.